As per the DelveInsight, the Amyotrophic Lateral Sclerosis prevalent population was 70,456 in 2017 in the seven major markets (i.e the USA, EU5, and Japan). In 2017, the Amyotrophic Lateral Sclerosis Market Size in 7MM was found to be USD 233.45 Million, which is expected to increase during the forecast period.
Some of the key factors such as Availability of genuine epidemiological data, robust pipeline activity and increasing awareness programs are expected to drive the Amyotrophic Lateral Sclerosis Market Growth in the coming years. However, the factors such as high medical cost, lack of proper diagnosis, high mortality rate, and dominance of a few drugs for treatment will impact the market growth.
Some of the key companies in the Amyotrophic Lateral Sclerosis Market includes Orphazyme, Biogen, Orion Pharma, Brainstorm Cell Therapeutics, AB Science, Alexion Pharmaceuticals, Cytokinetics, Biohaven Pharmaceuticals, MediciNova, Amylyx Pharmaceuticals, UCB Pharma, Clene Nanomedicine, AZTherapies, Cytokinetics/Astellas Pharma, Revalesio Corporation, Annexon, Samus Therapeutics, GlaxoSmithKline, Apellis Pharmaceuticals, and several others
For more detailed information, visit:
Amyotrophic Lateral Sclerosis Market Trends and Growth Analysis